Related Experiment Video
Updated: Mar 22, 2026
Partial Sciatic Nerve Ligation: A Mouse Model of Chronic Neuropathic Pain to Study the Antinociceptive Effect of Novel Therapies
Published on: October 6, 2022
The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats
Georgia Gris1, Enrique Portillo-Salido1, Bertrand Aubel1
1Department of Pharmacology, Drug Discovery &Preclinical Development, ESTEVE, Barcelona, Spain.
Abstract:
E-52862 is a selective σ1R antagonist currently undergoing phase II clinical trials for neuropathic pain and represents a potential first-in-class analgesic. Here, we investigated the effect of single and repeated administration of E-52862 on different pain-related behaviours in several neuropathic pain models in rats: mechanical allodynia in cephalic (trigeminal) neuropathic pain following chronic constriction injury of the infraorbital nerve (IoN), mechanical hyperalgesia in streptozotocin (STZ)-induced diabetic polyneuropathy, and cold allodynia in oxaliplatin (OX)-induced polyneuropathy. Mechanical hypersensitivity induced after IoN surgery or STZ administration was reduced by acute treatment with E-52862 and morphine, but not by pregabalin. In the OX model, single administration of E-52862 reversed the hypersensitivity to cold stimuli similarly to 100 mg/kg of gabapentin. Interestingly, repeated E-52862 administration twice daily over 7 days did not induce pharmacodynamic tolerance but an increased antinociceptive effect in all three models. Additionally, as shown in the STZ and OX models, repeated daily treatment with E-52862 attenuated baseline pain behaviours, which supports a sustained modifying effect on underlying pain-generating mechanisms. These preclinical findings support a role for σ1R in neuropathic pain and extend the potential for the use of selective σ1R antagonists (e.g., E-52862) to the chronic treatment of cephalic and extra-cephalic neuropathic pain.
Insights
E-52862, a sigma-1 receptor antagonist, effectively reduced neuropathic pain behaviors in rat models. Repeated E-52862 treatment enhanced analgesic effects without tolerance, suggesting potential for chronic pain management.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Neuropathic pain is a debilitating condition with limited treatment options.
- Selective sigma-1 receptor (σ1R) antagonists, like E-52862, show promise as novel analgesics.
- E-52862 is currently in phase II clinical trials for neuropathic pain treatment.
Purpose of the Study:
- To investigate the efficacy of single and repeated E-52862 administration in preclinical models of neuropathic pain.
- To evaluate the development of pharmacodynamic tolerance with repeated E-52862 treatment.
- To assess the potential of E-52862 for chronic neuropathic pain management.
Main Methods:
- E-52862's effects on mechanical allodynia, mechanical hyperalgesia, and cold allodynia were tested in rat models of neuropathic pain (infraorbital nerve constriction, streptozotocin-induced diabetes, oxaliplatin-induced neuropathy).
- Comparisons were made with morphine, pregabalin, and gabapentin.
- Single and repeated (7-day) administration protocols were employed.
Main Results:
- Acute E-52862 treatment reduced mechanical hypersensitivity in infraorbital nerve and streptozotocin models, comparable to morphine.
- E-52862 reversed cold allodynia in the oxaliplatin model, similar to gabapentin.
- Repeated E-52862 administration demonstrated no tolerance but an enhanced antinociceptive effect.
- Chronic E-52862 treatment attenuated baseline pain behaviors, indicating sustained effects on pain mechanisms.
Conclusions:
- Preclinical data strongly support a role for sigma-1 receptors in neuropathic pain.
- Selective σ1R antagonists, exemplified by E-52862, represent a promising therapeutic strategy for chronic neuropathic pain.
- E-52862's efficacy and lack of tolerance suggest its potential as a first-in-class chronic analgesic.
